Author

Huiyan Ying

University of HelsinkiORCID 0000-0001-5878-5718Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Mitro MiihkineniD· 2 shared Tero A. AittokallioiD· 2 shared Weikaixin KongiD· 2 shared Aron Schulman· 1 shared Jie Zhu· 1 shared Jordi MestresiD· 1 shared Kari J. KurppaiD· 1 shared Liting Huang· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Mitro MiihkinenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsbioRxivPreprintOct 26, 2026

Paired activity learning supports systematic identification of mutant-selective EGFR inhibitors

Jie Zhu, Weikaixin Kong, Liting Huang…·Tero A. Aittokallio

The paper develops a computational-experimental framework to identify mutant-selective EGFR inhibitors by leveraging paired activity measurements and structural analysis.

DOI 10.64898/2026.10.21.760684

humanproteomics

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintNov 12, 2025

Off-target mapping enhances selectivity of machine learning-predicted CK2 inhibitors

Huiyan Ying, Weikaixin Kong, Aron Schulman…·Mitro Miihkinen

The paper develops an ML-powered drug discovery pipeline to design selective CK2 inhibitors with favorable off-target profiles, achieving a 90% hit-rate.

DOI 10.1101/2025.11.12.688093

machine learning (classical)drug response / drug discovery

𝕏 PostBluesky